Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit

Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review

(2015) Hazem Elewa et al.   CLINICAL PHARMACOKINETICS

Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections

(2014) Taotao Wang et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Voriconazole Metabolism, Toxicity, and the Effect of Cytochrome P450 2C19 Genotype

(2014) Dimitrios Zonios et al.   JOURNAL OF INFECTIOUS DISEASES

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

(2014) Jason A Roberts et al.   LANCET INFECTIOUS DISEASES

CYP2C19Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?

(2014) Aniwaa Owusu Obeng et al.   PHARMACOTHERAPY

Potential Factors for Inadequate Voriconazole Plasma Concentrations in Intensive Care Unit Patients and Patients with Hematological Malignancies

(2013) Martin Hoenigl et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity

(2013) Yosuke Suzuki et al.   CLINICA CHIMICA ACTA

Risk Factors for Voriconazole Hepatotoxicity at 12 Weeks in Lung Transplant Recipients

(2012) M-L. Luong et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus Infections

(2012) Natalie K. Boyd et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring

(2012) Michael J. Dolton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial

(2012) Wan Beom Park et al.   CLINICAL INFECTIOUS DISEASES

Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis

(2012) Yukihiro Hamada et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Evaluation of Hepatotoxicity with Off-Label Oral-Treatment Doses of Voriconazole for Invasive Fungal Infections

(2010) Elizabeth Gorski et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Use of Intralesional Voriconazole for the Treatment of CutaneousScedosporium apiospermumInfection

(2010) Mariola Moreno Azofra et al.   CLINICAL INFECTIOUS DISEASES

Hepatic Safety of Voriconazole after Allogeneic Hematopoietic Stem Cell Transplantation

(2009) I. Amigues et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes

(2009) Kazuaki Matsumoto et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders

(2009) Koki Ueda et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

International Study of the Prevalence and Outcomes of Infection in Intensive Care Units

(2009) Jean-Louis Vincent   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

(2008) Thomas J. Walsh et al.   CLINICAL INFECTIOUS DISEASES

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES

Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes

(2007) A. Pascual et al.   CLINICAL INFECTIOUS DISEASES